Abstract

The performance of model-based bioprocess optimizations depends on the accuracy of the mathematical model. However, models of bioprocesses often have large uncertainty due to the lack of model identifiability. In the presence of such uncertainty, process optimizations that rely on the predictions of a single “best fit” model, e.g. the model resulting from a maximum likelihood parameter estimation using the available process data, may perform poorly in real life. In this study, we employed ensemble modeling to account for model uncertainty in bioprocess optimization. More specifically, we adopted a Bayesian approach to define the posterior distribution of the model parameters, based on which we generated an ensemble of model parameters using a uniformly distributed sampling of the parameter confidence region. The ensemble-based process optimization involved maximizing the lower confidence bound of the desired bioprocess objective (e.g. yield or product titer), using a mean-standard deviation utility function. We demonstrated the performance and robustness of the proposed strategy in an application to a monoclonal antibody batch production by mammalian hybridoma cell culture.

Highlights

  • Mathematical modeling has become an indispensible tool in bioprocess design and optimization (Kiparissides et al, 2011), especially after the implementation of Quality by Design for biopharmaceuticals by the US Food and Drug Administration (Rathore and Winkle, 2009)

  • We investigated the optimization of batch monoclonal antibody (mAb) production using hybridoma cells (Kiparissides et al, 2011; Kontoravdi et al, 2010; Tatiraju et al, 1999)

  • We presented an ensemble modeling based strategy to account for model uncertainty in optimizing bioprocesses

Read more

Summary

Introduction

Mathematical modeling has become an indispensible tool in bioprocess design and optimization (Kiparissides et al, 2011), especially after the implementation of Quality by Design for biopharmaceuticals by the US Food and Drug Administration (Rathore and Winkle, 2009). A model-based process optimization provides a quantitative and systematic framework to maximize process profitability, safety and reliability. In this context, batch process optimization is a topic of great interest and significance in (bio)pharmaceutical industry, especially in cell culture fermentation and crystallization separation processes. The creation of dynamic bioprocess models often faces significant challenges due to the high degree of process nonlinearity and limited amount of high-quality experimental data. The combination of these factors leads to model identifiability problem and to significant uncertainty in the resulting process model. Ignoring model uncertainty in a model-based process optimization could lead to poor real life performance (Nagy and Braatz, 2004)

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call